Advancing Single-Molecule De-Novo Protein Sequencing

UNOMR AG is developing a novel interface nanopore technology enabling single-molecule protein analysis with a specific focus on site-specific protein glycosylation occupancy and a clear development pathway toward true de-novo protein sequencing, addressing a critical gap in current proteomics and biomedical research methodologies that rely on indirect, ensemble-based approaches; within the framework of Horizon Europe Cluster Health Destination 5, and in particular the calls HORIZON-HLTH-2026-01-TOOL-03 on integrating New Approach Methodologies (NAMs) and HORIZON-HLTH-2026-01-TOOL-06 on supporting ERA actions to accelerate NAMs for biomedical research and regulatory testing of medicinal products and medical devices, UNOMR’s technology aims to provide an innovative, animal-free, high-resolution analytical NAM with strong relevance for mechanism-driven research, translational studies, biologics development, and regulatory science; UNOMR is open to participate both as Consortium/Coordinator seeking partners and as Partner seeking a Consortium/Coordinator, and is interested in collaboration with academic/industrial research groups in proteomics and glycoproteomics, pharmaceutical and biotechnology companies working on biologics and advanced therapies, NAM developers, and SMEs specialising in data analysis, AI-supported signal interpretation, instrumentation, and validation; within a consortium, UNOMR can contribute its nanopore sensor platform to method development, benchmarking, validation, and demonstration in biomedical and regulatory-relevant use cases, supporting ERA-wide coordination and dissemination activities, with the expected outcome of advancing the acceptance and adoption of next-generation NAMs, improving protein characterisation capabilities, reducing reliance on animal models, and strengthening European leadership in innovative protein analysis technologies.